These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

620 related items for PubMed ID: 15828836

  • 1. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Farquhar R, Guo Z, Qiu Y, Brodie AM.
    J Med Chem; 2005 Apr 21; 48(8):2972-84. PubMed ID: 15828836
    [Abstract] [Full Text] [Related]

  • 2. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
    Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM.
    Mol Cancer Ther; 2008 Aug 21; 7(8):2348-57. PubMed ID: 18723482
    [Abstract] [Full Text] [Related]

  • 3. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
    Njar VC, Kato K, Nnane IP, Grigoryev DN, Long BJ, Brodie AM.
    J Med Chem; 1998 Mar 12; 41(6):902-12. PubMed ID: 9526564
    [Abstract] [Full Text] [Related]

  • 4. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.
    Cancer Res; 2000 Dec 01; 60(23):6630-40. PubMed ID: 11118046
    [Abstract] [Full Text] [Related]

  • 5. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
    Nnane IP, Long BJ, Ling YZ, Grigoryev DN, Brodie AM.
    Br J Cancer; 2000 Jul 01; 83(1):74-82. PubMed ID: 10883671
    [Abstract] [Full Text] [Related]

  • 6. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.
    Handratta VD, Jelovac D, Long BJ, Kataria R, Nnane IP, Njar VC, Brodie AM.
    J Steroid Biochem Mol Biol; 2004 Oct 01; 92(3):155-65. PubMed ID: 15555909
    [Abstract] [Full Text] [Related]

  • 7. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
    Hou Q, He C, Lao K, Luo G, You Q, Xiang H.
    Steroids; 2019 Oct 01; 150():108384. PubMed ID: 30885648
    [Abstract] [Full Text] [Related]

  • 8. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
    Purushottamachar P, Godbole AM, Gediya LK, Martin MS, Vasaitis TS, Kwegyir-Afful AK, Ramalingam S, Ates-Alagoz Z, Njar VC.
    J Med Chem; 2013 Jun 27; 56(12):4880-98. PubMed ID: 23713567
    [Abstract] [Full Text] [Related]

  • 9. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T, Bertolini R, Nichols SE, Setoud R, Frey FJ, Baker ME, Frey BM.
    Biochem Pharmacol; 2011 Dec 01; 82(11):1651-62. PubMed ID: 21907706
    [Abstract] [Full Text] [Related]

  • 10. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
    Grigoryev DN, Long BJ, Nnane IP, Njar VC, Liu Y, Brodie AM.
    Br J Cancer; 1999 Oct 01; 81(4):622-30. PubMed ID: 10574247
    [Abstract] [Full Text] [Related]

  • 11. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT, Nakamura J, Li JS, Ling YZ, Son C, Kemppainen JA, Wilson EM, Brodie AM.
    Cancer Res; 1996 Nov 01; 56(21):4956-64. PubMed ID: 8895750
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic profile of 3beta-hydroxy-17-(1H-1,2,3-triazol-1-yl)androsta-5,16-diene (VN/87-1), a potent androgen synthesis inhibitor, in mice.
    Nnane IP, Njar VC, Brodie AA.
    J Steroid Biochem Mol Biol; 2001 Sep 01; 78(3):241-6. PubMed ID: 11595504
    [Abstract] [Full Text] [Related]

  • 13. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E, Zauhar RJ.
    J Chem Inf Model; 2012 Oct 22; 52(10):2670-83. PubMed ID: 22924551
    [Abstract] [Full Text] [Related]

  • 14. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H.
    Prostate; 2011 Sep 22; 71(12):1344-56. PubMed ID: 21308717
    [Abstract] [Full Text] [Related]

  • 15. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
    Njar VC, Brodie AM.
    J Med Chem; 2015 Mar 12; 58(5):2077-87. PubMed ID: 25591066
    [Abstract] [Full Text] [Related]

  • 16. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
    Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, Stein CA.
    J Biol Chem; 2012 Feb 03; 287(6):3777-87. PubMed ID: 22174412
    [Abstract] [Full Text] [Related]

  • 17. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 03; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 18. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
    Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, Auchus RJ, Sharifi N.
    Clin Cancer Res; 2012 Jul 01; 18(13):3571-9. PubMed ID: 22753664
    [Abstract] [Full Text] [Related]

  • 19. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, Tachibana K, Shiraishi T, Yoshino H, Honma A, Emura T, Ohta M, Nakagawa T, Houjo T, Corey E, Vessella RL, Aoki Y, Sato H.
    Int J Oncol; 2015 Apr 01; 46(4):1560-72. PubMed ID: 25634071
    [Abstract] [Full Text] [Related]

  • 20. Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model.
    Thankan RS, Thomas E, Purushottamachar P, Weber DJ, Njar VCO.
    Bioorg Chem; 2023 Oct 01; 139():106700. PubMed ID: 37392559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.